The suppression of prion propagation using poly-l-lysine by targeting plasminogen that stimulates prion protein conversion

Biomaterials

Volumn 32, Issue 11, 2011, Pages 3141-3149

  Ryou, Chongsuk ^a,b   Titlow, William B ^a   Mays, Charles E ^b   Bae, Younsoo ^b   Kim, Sehun ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cofactor; Plasminogen; Poly l lysine; Prion conversion; Therapeutic target; Translational research

Indexed keywords

COFACTORS; PLASMINOGEN; POLY-L-LYSINE; PRION CONVERSION; THERAPEUTIC TARGETS; TRANSLATIONAL RESEARCH;

ANIMAL CELL CULTURE; ANIMALS; CELL CULTURE; DRUG DELIVERY; SCANDIUM;

AMINO ACIDS;

LYSINE; PLASMINOGEN; POLYLYSINE; POLYLYSINE 50; PRION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; MOUSE; NONHUMAN; PRION; PRION DISEASE; PRIORITY JOURNAL; VIRUS REPLICATION;

ANIMALS; BRAIN; CELL LINE, TUMOR; HUMANS; MICE; PLASMINOGEN; POLYLYSINE; PRION DISEASES; PRIONS; PRPC PROTEINS; PRPSC PROTEINS;

ANIMALIA;

EID: 79951578113     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.01.017     Document Type: Article

References (35)

1. Meister A. Biochemistry of the amino acids 1965, Academic Press, New York. 2nd ed.
2. Langeland N., Moore L.J., Holmsen H., Haarr L. Interaction of polylysine with the cellular receptor for herpes simplex virus type 1. J Gen Virol 1988, 69(6):1137-1145.
3. Nicholas Delihas L.W.R., Winnie Loo, Jonathan Berkowitz, Natalia Poltoratskaia High sensitivity of mycobacterium species to the bactericidal activity by polylysine. FEMS Microbiol Lett 1995, 132(3):233-237.
4. Shima S., Matsuoka H., Iwamoto T., Sakai H. Antimicrobial action of epsilon-poly-l-lysine. J Antibiot 1984, 37(11):1449-1455.
5. Arnold L.J.J., Dagan A., Gutheil J., Kaplan N.O. Antineoplastic activity of poly(l-lysine) with some ascites tumor cells. Proc Natl Acad Sci U S A 1979, 76:3246-3250.
6. Bareford L.M., Swaan P.W. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 2007, 59(8):748-758.
7. Xu B., Wiehle S., Roth J.A., Cristiano R.J. The contribution of poly-l-lysine, epidermal growth factor and streptavidin to EGF/PLL/DNA polyplex formation. Gene Ther 1998, 5:1235-1243.
8. Wagner E., Cotten M., Foisner R., Birnstiel M.L. Transferrin-polycation-DNA complexes: the effect of polycations on the structure of the complex and DNA delivery to cells. Proc Natl Acad Sci U S A 1991, 88(10):4255-4259.
9. Plank C., Tang M.X., Wolfe A.R., Szoka F.C. Branched cationic peptides for gene delivery: role of type and number of cationic residues in formation and in vitro activity of DNA polyplexes. Hum Gene Ther 1999, 10(2):319-332.
10. Klink D., Yu Q.-C., Glick M.C., Scanlin T. Lactosylated poly-l-lysine targets a potential lactose receptor in cystic fibrosis and non-cystic fibrosis airway epithelial cells. Mol Ther 2003, 7(1):73-80.
11. Ward C.M., Read M.L., Seymour L.W. Systemic circulation of poly(l-lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapy. Blood 2001, 97(8):2221-2229.
12. Harada-Shiba M., Yamauchi K., Harada A., Takamisawa I., Shimokado K., Kataoka K. Polyion complex micelles as vectors in gene therapy - pharmacokinetics and in vivo gene transfer. Gene Ther 2002, 9:407-414.
13. Sakharov D.V., Jie A.F.H., Bekkers M.E.A., Emeis J.J., Rijken D.C. Polylysine as a vehicle for extracellular matrix-targeted local drug delivery, providing high accumulation and long-term retention within the vascular wall. Arterioscler Thromb Vasc Biol 2001, 21(6):943-948.
14. Prusiner S.B. Novel proteinaceous infectious particles cause scrapie. Science 1982, 216:136-144.
15. Prusiner S.B. Prions. Proc Natl Acad Sci U S A 1998, 95:13363-13383.
16. Prusiner S.B. Molecular biology of prion diseases. Science 1991, 252:1515-1522.
17. Trevitt C.R., Collinge J. A systematic review of prion therapeutics in experimental models. Brain 2006, 129(9):2241-2265.
18. Mays C.E., Ryou C. Plasminogen stimulates propagation of protease-resistant prion protein in vitro. FASEB J 2010, 24(12):5102-5112.
19. Fischer M.B., Roeckl C., Parizek P., Schwarz H.P., Aguzzi A. Binding of disease-associated prion protein to plasminogen. Nature 2000, 408:479-483.
20. Ryou C., Prusiner S.B., Legname G. Cooperative binding of dominant-negative prion protein to kringle domains. J Mol Biol 2003, 329:323-333.
21. Mays C.E., Ryou C. Plasminogen: a cellular protein cofactor for PrPSc propagation. Prion 2011, 5(1):22-27.
22. Scott M.R.D., Butler D.A., Bredesen D.E., Walchli M., Hsiao K.K., Prusiner S.B. Prion protein gene expression in cultured cells. Protein Eng 1988, 2:69-76.
23. Mays C.E., Kang H.-E., Kim Y., Shim S.H., Bang J.-E., Woo H.-J., et al. CRBL cells: establishment, characterization and susceptibility to prion infection. Brain Res 2008, 1208:170-180.
24. Ryou C., Legname G., Peretz D., Craig J.C., Baldwin M.A., Prusiner S.B. Differential inhibition of prion propagation by enantiomers of quinacrine. Lab Invest 2003, 83:837-843.
25. Saborio G.P., Permanne B., Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2001, 411:810-813.
26. Mays C.E., Titlow W., Seward T., Telling G.C., Ryou C. Enhancement of protein misfolding cyclic amplification by using concentrated cellular prion protein source. Biochem Biophys Res Commun 2009, 388(2):306-310.
27. Kim Y., Song J., Mays C., Titlow W., Yoon D., Ryou C. Changes in gene expression of kringle domain-containing proteins in murine brains and neuroblastoma cells infected by prions. Mol Cell Biochem 2009, 328:177-182.
28. De Vries A., Feldman J.D., Stein O., Stein Y., Katchalski E. Effects of intravenously administered poly-DL-lysine in rats. Proc Soc Exp Biol Med 1953, 76:237-240.
29. Schick B.P., Maslow D., Moshinski A., Antonio J.D.S. Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo. Blood 2004, 103(4):1356-1363.
30. May B.C.H., Fafarman A.T., Hong S.B., Rogers M., Deady L.W., Prusiner S.B., et al. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc Natl Acad Sci U S A 2003, 100:3416-3421.
31. Supattapone S., Nguyen H.-O.B., Cohen F.E., Prusiner S.B., Scott M.R. Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci U S A 1999, 96(25):14529-14534.
32. Supattapone S., Wille H., Uyechi L., Safar J., Tremblay P., Szoka F.C., et al. Branched polyamines cure prion-infected neuroblastoma cells. J Virol 2001, 75:3453-3461.
33. Lim Y.-B., Mays C.E., Kim Y., Titlow W.B., Ryou C. The inhibition of prions through blocking prion conversion by permanently charged branched polyamines of low cytotoxicity. Biomaterials 2010, 31(8):2025-2033.
34. White M.D., Farmer M., Mirabile I., Brandner S., Collinge J., Mallucci G.R. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci U S A 2008, 105(29):10238-10243.
35. Soto C., Kascsak R.J., Saborio G.P., Aucouturier P., Wisniewski T., Prelli F., et al. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet 2000, 355:192-197.